Biological 3D printing developer BioLife4D has filed for a $50 million initial public offering as it looks to commercialize its cardiac tissue regeneration and organ replacement processes.
The Chicago-based company said yesterday it is developing technologies with an end goal of creating a 3D bioprinted viable human heart suitable for transplant.
Funds from the offering are slated to support working capital and fund initiatives which include expanding personnel, acquiring additional laboratory space and licensing related technologies.
“Heart disease is the leading cause of death worldwide – killing one in four men and one in three women while outpacing all forms of cancer combined. BioLife4D is committed to transforming the treatment of heart disease, capitalizing on recent medical breakthroughs and optimizing a process that will ultimately give patients the gift of time. BioLife4D is bringing revolutionary life-saving care to the masses, and we want the masses to have a chance to be a part of this revolution. Equity crowdfunding can help us accomplish this important objective, and we’re extremely excited for interested investors to join us,” BioLife4D CEO Steven Morris said in a press release.
BioLife4D said its primary focus will be making viable organ replacement a “safe, accessible and affordable reality.”